gamma-aminobutyric acid has been researched along with Cannabis Abuse in 12 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Disrupted brain gamma-aminobutyric acid (GABA)/glutamate homeostasis is a promising target for pharmacological intervention in co-occurring bipolar disorder (BD) and cannabis use disorder (CUD)." | 5.51 | Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders. ( Arnold, L; Hix, S; Mellick, W; Prisciandaro, JJ; Squeglia, LM; Tolliver, BK, 2022) |
| "Gabapentin is a safe and well-tolerated medication, FDA-approved to treat other neurological diseases, that restores GABA/glutamate homeostasis, with treatment studies supporting efficacy in treating CUD, as well as anxiety and sleep disorders that are common to both BD and CUD." | 3.11 | Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders. ( Arnold, L; Hix, S; Mellick, W; Prisciandaro, JJ; Squeglia, LM; Tolliver, BK, 2022) |
| "Gabapentin was also associated with significantly greater improvement in overall performance on tests of executive function (p=0." | 2.77 | A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. ( Adusumalli, M; Begovic, A; Buffkins, K; Crean, R; Goodell, V; Kyle, M; Light, JM; Mason, BJ; Quello, S; Rao, S; Shadan, F, 2012) |
| "Cannabis withdrawal symptoms were assessed using the Marijuana Withdrawal Checklist." | 2.77 | A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. ( Adusumalli, M; Begovic, A; Buffkins, K; Crean, R; Goodell, V; Kyle, M; Light, JM; Mason, BJ; Quello, S; Rao, S; Shadan, F, 2012) |
| "Problematic compounds may cause seizures either acutely or on withdrawal: Their use may reduce effectiveness of antiepileptic drugs, or may simply promote and enhance chaotic lifestyles." | 2.48 | Alcohol and drugs in epilepsy: pathophysiology, presentation, possibilities, and prevention. ( Borland, W; Leach, JP; Mohanraj, R, 2012) |
| "Conventional wisdom, and even well-reasoned theoretical mechanisms, suggests that the chronic use of psychoactive substances would impair cognitive functioning of individuals." | 2.42 | Cognitive impairment in substance abuse. ( Cellucci, T; Hedt, J; Jarchow, A; Vik, PW, 2004) |
| "Treatment with topiramate or pregabalin blocked the decrease of TH and the increase of CB1 gene expressions induced by cannabinoid withdrawal." | 1.39 | Pregabalin and topiramate regulate behavioural and brain gene transcription changes induced by spontaneous cannabinoid withdrawal in mice. ( Almela, P; Aracil-Fernández, A; Manzanares, J, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 10 (83.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Prisciandaro, JJ | 1 |
| Mellick, W | 1 |
| Squeglia, LM | 1 |
| Hix, S | 1 |
| Arnold, L | 1 |
| Tolliver, BK | 1 |
| Papazisis, G | 1 |
| Garyfallos, G | 1 |
| Sardeli, C | 1 |
| Kouvelas, D | 1 |
| Laprevote, V | 1 |
| Schwan, R | 1 |
| Schwitzer, T | 1 |
| Rolland, B | 1 |
| Thome, J | 1 |
| Lile, JA | 1 |
| Wesley, MJ | 1 |
| Kelly, TH | 1 |
| Hays, LR | 1 |
| Rubino, T | 1 |
| Parolaro, D | 1 |
| Sherman, BJ | 1 |
| McRae-Clark, AL | 1 |
| Gorelick, DA | 1 |
| Aracil-Fernández, A | 1 |
| Almela, P | 1 |
| Manzanares, J | 1 |
| Horey, JT | 1 |
| Mariani, JJ | 1 |
| Cheng, WY | 1 |
| Bisaga, A | 1 |
| Sullivan, M | 1 |
| Nunes, E | 1 |
| Levin, FR | 1 |
| Mason, BJ | 1 |
| Crean, R | 1 |
| Goodell, V | 1 |
| Light, JM | 1 |
| Quello, S | 1 |
| Shadan, F | 1 |
| Buffkins, K | 1 |
| Kyle, M | 1 |
| Adusumalli, M | 1 |
| Begovic, A | 1 |
| Rao, S | 1 |
| Leach, JP | 1 |
| Mohanraj, R | 1 |
| Borland, W | 1 |
| Vik, PW | 1 |
| Cellucci, T | 1 |
| Jarchow, A | 1 |
| Hedt, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gabapentin for Bipolar & Cannabis Use Disorders[NCT03334721] | Phase 2 | 23 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| Gabapentin for Cannabis Withdrawal and Use[NCT00395044] | Phase 2 | 50 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA, normalized to water and corrected for CSF%, in dorsal anterior cingulate measured via Proton Magnetic Resonance Spectroscopy. (NCT03334721)
Timeframe: Day 5 of each experimental condition
| Intervention | Institutional Units (Mean) | |
|---|---|---|
| GABA (randomization order 1, gabapentin 1st) | GABA (randomization order 2, placebo 1st) | |
| Gabapentin | 2.625 | 2.609 |
| Placebo Oral Capsule | 2.696 | 2.720 |
The D-KEFS is a testing battery designed to measure executive functioning, a critical component of participating in cognitive behavioral therapy used to treat marijuana dependence. Data were obtained from the D-KEFS test instruments completed at baseline and week 4, which included the Trail Making Test, Verbal Fluency Test, and Color-Word Interference Test. Scaled scores range from 1 (worst) to 19 (best). Change = (Week 4 score - Week 0 score). Positive values indicate increased executive functioning. (NCT00395044)
Timeframe: Week 0 and Week 4
| Intervention | scores on a scale (Mean) |
|---|---|
| Gabapentin | .28 |
| Placebo | -.20 |
Urinary THC/Cr ratio, also known as CN-THCCOOH (creatinine normalized tetrahydrocannabinol carboxylic acid), is a highly sensitive and specific quantitative analytic procedure to determine current marijuana metabolite levels in the urine as well as new marijuana use or abstinence. Gas chromatography-mass spectrometric levels of 11-nor-9-carboxy-9-THC (THC-COOH), the primary marijuana metabolite, are normalized to the urine creatinine (CN) concentration to reduce the variability of drug measurement attributable to urine dilution. Negative values indicate decreased use. (NCT00395044)
Timeframe: Week 0 and Week 12
| Intervention | ng/ml (Mean) |
|---|---|
| Gabapentin | -966.00 |
| Placebo | -532.81 |
The MPS is an instrument to assess the incidence of physical, psychological, social, and functioning problems that can result from cannabis dependence. The Total score ranges from 0-38 where 0=best outcome and 38=worst outcome. Change = (Week 12 score - Week 0 score). (NCT00395044)
Timeframe: Week 0 and Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | -3.40 |
| Placebo | -4.90 |
The Marijuana Craving question of the Marijuana Withdrawal Checklist assesses severity of craving to smoke marijuana. The craving question is rated on a scale of 0-3 where 0=best outcome (no symptoms) and 3=worst outcome (severe symptoms). Change = (Week 12 score - Week 0 score). (NCT00395044)
Timeframe: Week 0 and Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | -1.55 |
| Placebo | -1.46 |
The BDI-II is a self-rating of severity of depressive symptoms. The Total score range on the BDI-II is from 0-63; 0=best outcome; 63=worst outcome. Change = (Week 12 score - Week 0 score). (NCT00395044)
Timeframe: Week 0 and Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 3.71 |
| Placebo | 5.22 |
The MWC is an instrument to assess the severity of frequently reported cannabis withdrawal symptoms. Each question on the measure is recorded as a severity rating between 0-3: 0=best outcome; 3=worst outcome. The severity rating of each question was averaged to obtain a single marijuana withdrawal severity score. Change = (Week 12 score - Week 0 score). (NCT00395044)
Timeframe: Week 0 and Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 1.42 |
| Placebo | 2.12 |
The PSQI is an instrument to assess subjective sleep quality and disturbance. The range on the measure is from 0-21: 0=best outcome; 21=worst outcome. Change = (Week 12 score - Week 0 score). (NCT00395044)
Timeframe: Week 0 and Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | -4.27 |
| Placebo | -1.72 |
6 reviews available for gamma-aminobutyric acid and Cannabis Abuse
| Article | Year |
|---|---|
Is There a Place for Off-Label Pharmacotherapy in Cannabis Use Disorder? A Review on Efficacy and Safety.
Topics: Acetylcysteine; Amines; Cannabidiol; Cyclohexanecarboxylic Acids; Dronabinol; Drug Combinations; Gab | 2015 |
The Impact of Exposure to Cannabinoids in Adolescence: Insights From Animal Models.
Topics: Adolescent; Animals; Brain; Cannabinoids; Cognition; Disease Models, Animal; Endocannabinoids; gamma | 2016 |
Treatment of Cannabis Use Disorder: Current Science and Future Outlook.
Topics: Acetylcysteine; Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Health Ser | 2016 |
Pharmacological Treatment of Cannabis-Related Disorders: A Narrative Review.
Topics: Acetylcysteine; Amines; Animals; Cannabis; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyr | 2016 |
Alcohol and drugs in epilepsy: pathophysiology, presentation, possibilities, and prevention.
Topics: Alcohol Drinking; Alcohol Withdrawal Seizures; Alcoholism; Amphetamine-Related Disorders; Benzodiaze | 2012 |
Cognitive impairment in substance abuse.
Topics: Alcohol Amnestic Disorder; Amphetamines; Central Nervous System Stimulants; Cognition Disorders; Eth | 2004 |
3 trials available for gamma-aminobutyric acid and Cannabis Abuse
| Article | Year |
|---|---|
Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders.
Topics: Adolescent; Adult; Bipolar Disorder; Cigarette Smoking; Double-Blind Method; Female; Gabapentin; gam | 2022 |
Comparison of substance use milestones in cannabis- and cocaine-dependent patients.
Topics: Adult; Age of Onset; Amines; Antidepressive Agents, Second-Generation; Bupropion; Cocaine-Related Di | 2012 |
A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults.
Topics: Adolescent; Adult; Amines; Calcium Channel Blockers; Cannabis; Counseling; Cyclohexanecarboxylic Aci | 2012 |
3 other studies available for gamma-aminobutyric acid and Cannabis Abuse
| Article | Year |
|---|---|
Pregabalin abuse after past substance-seeking behavior.
Topics: Alcohol Drinking; Anti-Anxiety Agents; Anxiety Disorders; Behavior, Addictive; Drug-Seeking Behavior | 2013 |
Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol.
Topics: Amines; Analysis of Variance; Blood Pressure; Body Temperature; Cyclohexanecarboxylic Acids; Discrim | 2016 |
Pregabalin and topiramate regulate behavioural and brain gene transcription changes induced by spontaneous cannabinoid withdrawal in mice.
Topics: Analysis of Variance; Animals; Anticonvulsants; Anxiety; Behavior, Animal; Body Temperature; Cannabi | 2013 |